StockData

DBV Technologies vs Fate Therapeutics

DBVT and FATE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DBVT and FATE compare

DBV Technologies is the larger company, worth 26 times as much as Fate Therapeutics ($3.2B against $122M).

Fate Therapeutics grew revenue faster over the last twelve months (−23.4% versus −31.6% for DBV Technologies).

Fate Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1941% compared with −5405% at DBV Technologies.

Fate Therapeutics scores higher on the StockData Score (8 against 6 for DBV Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDBVTFATE
Size and price
Market cap$3.2B$122M
Share price$10.27$1.02
Change, 1 year−21.4%5.8%
Change, 5 years71.2%−98.1%
Beta (5Y)−0.083.98
Employees125161
StockData Score
Total score68 (better)
Valuation score03 (better)
Growth score00
Performance score00
Health score6 (better)5
Dividend score00
Valuation
P/S842×18.8× (better)
P/B21.7×0.8× (better)
FCF yield−5.9% (better)−86.4%
Fair value–$1.34
Margin of safety–23.8%
Growth
Revenue growth (TTM)−31.6%−23.4% (better)
Revenue growth, 5Y average−13.0% (better)−26.7%
Profitability
Operating margin−5432%−2058% (better)
Net margin−5405%−1941% (better)
FCF margin−4998%−1627% (better)
Return on equity−206%−60.7% (better)
Return on invested capital–−553%
Financial health
Debt / equity0.000.00
Current ratio3.244.85 (better)
Altman Z-score24.42 (better)−8.99
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions6.8%59.9%
Held by insiders12.1%25.7%
Insider net buying, 12 months−$15.5M−$336K (better)
Superinvestors holding1–
Short interest, % of float–11.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.